Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
- PMID: 35301096
- DOI: 10.1016/j.annonc.2022.03.003
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Conflict of interest statement
Disclosure MMR reports funding from Pfizer for palbociclib trials at IBCSG and DFCI. The remaining authors declare no conflict of interest relevant to this letter.
Comment on
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.Ann Oncol. 2021 Dec;32(12):1571-1581. doi: 10.1016/j.annonc.2021.09.015. Epub 2021 Oct 14. Ann Oncol. 2021. PMID: 34656740 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical